Sat. May 25th, 2024

Key Points:

  • Roche will acquire select parts of LumiraDx group related to the company’s point-of-care technology.
  • The acquisition is expected to close by mid-2024, with Roche paying $295 million at closing and an additional $55 million for reimbursement of funds.
  • LumiraDx’s technology integrates multiple point-of-care tests on a single instrument, providing affordable and accessible testing for patients globally. The platform offers a range of immunoassay and clinical chemistry tests.
  • The acquisition will enable Roche to transform testing at the point of care and expand its reach in decentralized healthcare settings worldwide.

Roche has announced plans to acquire select parts of the LumiraDx group, a company specializing in point-of-care technology. The transaction, expected to close by mid-2024, will involve Roche paying $295 million at closing and an additional $55 million for reimbursement of funds related to the point-of-care technology platform business. Once the deal is finalized, the acquired entities will be fully integrated into Roche Diagnostics.

LumiraDx’s point-of-care technology integrates multiple tests on a single instrument, making testing more affordable and accessible for patients globally. The platform offers a range of immunoassay and clinical chemistry tests and has the potential to include additional high-value medical tests in the future. These tests can be stored at room temperature, allowing for convenient handling in decentralized healthcare settings.

Matt Sause, CEO of Roche Diagnostics, believes that the addition of LumiraDx’s technology will transform testing at the point of care and improve patient access to timely results in decentralized healthcare settings worldwide. Roche aims to leverage LumiraDx’s versatile platform to provide better diagnostic testing for a range of diseases and technologies. Veronique Ameye, CEO of LumiraDx, expressed excitement about the acquisition and believes it will enable more patients to access fast and easy diagnostic testing.

This acquisition reflects Roche’s commitment to advancing healthcare technologies and improving patient care. By integrating LumiraDx’s point-of-care technology into its diagnostics portfolio, Roche aims to expand its reach and provide innovative solutions for patients around the globe.

Related Post